A recent article has reported an exceptional durable response (of >5 years) to compassionate targeted entrectinib ALK/TrkA inhibitory therapy in an infant with relapsed refractory metastatic NB within a context of exhausted therapeutic options [34]. This evidence concerns the gene NTRK1 and neuroblastoma.